Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia

Cancer Research

Volumn 69, Issue 1, 2009, Pages 185-192

  Pagel, John M ^a,d   Matthews, Dana C ^b   Kenoyer, Aimee ^a   Hamlin, Donald K ^b   Wilbur, Daniel S ^b   Fisher, Darrell R ^c   Gopal, Ajay K ^a   Lin, Yukang ^a   Saganic, Laura ^a   Appelbaum, Frederick R ^a   Press, Oliver W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; CD45 ANTIGEN; CYCLIC GMP; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; MONOCLONAL ANTIBODY CD45 STREPTAVIDIN CONJUGATE; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ARTICLE; BIOTINYLATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIAGNOSTIC IMAGING; DRUG EFFICACY; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPHOID TISSUE; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRETARGETED RADIOIMMUNOTHERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RECURRENT DISEASE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; BIOTIN; FEMALE; HUMANS; IMMUNOTOXINS; INDIUM RADIOISOTOPES; LEUKEMIA, MYELOID; LYMPHOID TISSUE; MALE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 58249111462     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2513     Document Type: Article

References (29)

1. Appelbaum F, Matthews D, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992;54:829-33.
2. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991;9:478-90.
3. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support [see comments]. N Engl J Med 1993;329:1219-24.
4. Gopal AK, Pagel JM, Rajendran JG, et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant 2006;12:697-702.
5. Nakano A, Harada T, Morikawa S, Kato Y. Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines. Acta Pathol Jpn 1990;40:107-15.
6. Taetle R, Ostergaard H, Smedsrud M, Trowbridge I. Regulation of CD45 expression in human leukemia cells. Leukemia 1991;5:309-14.
7. Friesen C, Glatting G, Koop B, et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 2007;67:1950-8.
8. Glatting G, Muller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med 2006;47:1335-41.
9. Jurcic JG. Immunotherapy for acute myeloid leukemia. Curr Oncol Rep 2005;7:339-46.
10. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant 2005;36:1021-6.
11. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94:1237-47.
12. Pagel J, Appelbaum F, Sandmaier B, et al. 131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood 2005;106.
13. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006;107:2184-91.
14. Pagel J, Gooley T, Rajendran J, et al. Targeted radiotherapy using 131i-anti-CD45 antibody followed by allogeneic hematopoietic cell transplantation (HCT): the relationships among dosimetry, bone marrow uptake, and relapse. Eur J Nucl Med Mol Imaging 2006;33:S193.
15. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34.
16. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999;14:153-66.
17. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802-7.
18. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001;98:2535-43.
19. Pagel J, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003;101:2340-8.
20. Pagel JM, Hedin N, Drouet L, et al. Conventional and pretargeted radioimmunotherapy using an anti-murine CD45 monoclonal antibody in a syngeneic, disseminated murine leukemia model. Blood 2006;111:2261-8.
21. Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006;66:3884-92.
22. Yao Z, Zhang M, Garmestani K, et al. Pretargeted a emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N′, N″,N‴-tetraacetic acid-biotin. Clin Cancer Res 2004;10:3137-46.
23. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/ lymphoma xenografts. Proc Natl Acad Sci U S A 2003;100:1891-5.
24. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res 1992;52:1228-34.
25. Onthank DC, Liu S, Silva PJ, et al. 90Y and 111In complexes of a DOTA-conjugated integrin α v β 3 receptor antagonist: different but biologically equivalent. Bioconjug Chem 2004;15:235-41.
26. Leonard JP, Siegel JA, Goldsmith SJ, et al. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma 90Y and 111In complexes of a DOTA-conjugated integrin α v β 3 receptor antagonist: different but biologically equivalent. Cancer Invest 2003;21:241-52.
27. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008;49:158-63.
28. Goldenberg DM, Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene 2007;26:3734-44.
29. Sharkey RM, Karacay H, Litwin S, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68:5282-90.